For providers · Clinical resource

Referring a patient with PMDD: an NC provider guide

Refer a patient for psychiatric PMDD care when premenstrual mood symptoms are severe enough to impair function, when they are not fully explained by another disorder, or when first-line management in your setting has not controlled them. Because PMDD is confirmed by prospective daily symptom ratings across at least two cycles (StatPearls), the most useful thing you can do before or alongside a referral is start the patient charting — the diagnosis is often still forming when she is referred. This guide is education for referring providers; it does not replace your clinical judgment for an individual patient.

PMDD is under-recognized and frequently dismissed as ordinary PMS, so patients often present to primary care, OB/GYN, or a therapist rather than to psychiatry. The screening is not the hard part; the “severe premenstrual mood symptoms — now what” step is. This guide covers who to suspect it in, how to confirm versus refer, and where to send a patient in North Carolina.

Who should I suspect PMDD in?

A patient with recurrent, cyclical mood symptoms — irritability, depressed mood, anxiety, or lability — that cluster in the luteal phase and remit within a few days of menses, and that impair work or relationships. Roughly 5% to 8% of menstruating patients have moderate-to-severe premenstrual symptoms with real functional impairment (StatPearls). Suspect it particularly when a patient reports a monthly, predictable collapse in function, when contraceptive or lifestyle measures have not helped, or when a “treatment-resistant depression” turns out on questioning to have a premenstrual rhythm.

Do I confirm the diagnosis or refer first?

Either order works, but the charting should start early regardless. The DSM-5-TR criteria require confirmation by prospective daily ratings across at least two consecutive symptomatic cycles; a provisional diagnosis is reasonable in the interim, but retrospective report is not sufficient (StatPearls). The validated instrument is the Daily Record of Severity of Problems (DRSP), and standardized scoring systems exist to make the DSM-5 determination from two or more cycles of DRSP data (C-PASS).

Practically: if you have the follow-up capacity to review two cycles of charting, starting it in your office speeds everything downstream. If you would rather hand off, refer now and note that charting has begun — the psychiatric evaluation will build on it. Either way, see prospective symptom charting for PMDD for exactly what to have the patient track.

How do I tell PMDD from premenstrual exacerbation?

By whether symptoms are present between periods. This is the distinction that most changes management. In PMDD, the follicular phase is essentially symptom-free; DSM-5 Criterion C requires that the disturbance not merely represent the premenstrual exacerbation of another disorder (StatPearls). Premenstrual exacerbation (PME) of an underlying depression, anxiety, or bipolar disorder looks similar in the luteal phase but does not clear after menses — the baseline disorder persists all month and simply worsens premenstrually. Prospective charting reveals which one you are looking at, because it captures the follicular phase, not just the bad week. The full differential is in PMDD or PME? a differential guide for providers.

The distinction matters because PME is treated by optimizing the underlying disorder, whereas PMDD responds to cycle-targeted treatment — including SSRI dosing options that PME does not share.

What treatment will the patient receive?

First-line pharmacologic treatment is an SSRI, with an option PMDD does not share with most mood disorders: luteal-phase-only dosing. ACOG’s clinical guideline names SSRIs as first-line for the affective symptoms of premenstrual disorders and notes that sertraline, paroxetine, and fluoxetine carry FDA approval for PMDD; it also recommends combined oral contraceptives, cognitive behavioral therapy, and — for severe or refractory disease — GnRH agonists with add-back therapy (ACOG CPG No. 7). A psychiatric prescriber can offer continuous or luteal-phase SSRI regimens, weigh a drospirenone-containing contraceptive where appropriate, and coordinate with any therapy already in place. Setting this expectation helps a hesitant patient accept the referral.

What about safety?

PMDD carries a meaningfully elevated risk of suicidal ideation and attempts, and the cyclical timing can make that risk easy to under-weight (Osborn et al.). Ask directly about premenstrual suicidal thoughts, and escalate rather than wait for an intake slot when they are present.

If a patient is in crisis, direct her to call or text 988 (Suicide & Crisis Lifeline) or call 911. For an urgent psychiatric handoff, note the acuity when you refer so intake can prioritize.

How do I refer to MCW?

Mindful Counseling & Wellness provides telehealth psychiatric evaluation and medication management for adults across North Carolina, led by a board-certified psychiatric mental health nurse practitioner (PMHNP-BC) with a focus on reproductive and perinatal mental health. Refer when premenstrual mood symptoms impair function, when the diagnosis needs confirmation and treatment, or when your first-line management has fallen short.

To refer, call (919) 739-3808 or email — patient name and contact are enough to start, and no clinical records (and no patient health details by email) are needed. For the timing of when to hand off, see when to refer a patient with PMDD; for the reproductive-mental-health context, see the perinatal mental health referral guide for NC providers. Patients researching their own care can read the patient PMDD guide. If you have a patient who fits now, start a referral.

Share this resource on LinkedIn · Follow Josephine W. Hazeley, PMHNP-BC on LinkedIn